The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Impact of Cross-Coupling Reactions in Drug Discovery and Development
Open accessAbstract
Cross-coupling reactions have played a critical role enabling the rapid expansion of structure–activity relationships (SAR) during the drug discovery phase to identify a clinical candidate and facilitate subsequent drug development processes. The reliability and flexibility of this methodology have attracted great interest in the pharmaceutical industry, becoming one of the most used approaches from Lead Generation to Lead Optimization. In this mini-review, we present an overview of cross-coupling reaction applications to medicinal chemistry efforts, in particular the Suzuki–Miyaura and Buchwald–Hartwig cross-coupling reactions as a remarkable resource for the generation of carbon–carbon and carbon–heteroatom bonds. To further appreciate the impact of this methodology, the authors discuss some recent examples of clinical candidates that utilize key cross-coupling reactions in their large-scale synthetic process. Looking into future opportunities, the authors highlight the versatility of the cross-coupling reactions towards new chemical modalities like DNA-encoded libraries (DELs), new generation of peptides and cyclopeptides, allosteric modulators, and proteolysis targeting chimera (PROTAC) approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Daina, A., Michielin, O., & Zoete, V. (2017) · Scientific Reports · doi:10.1038/srep42717 · Cited by 18,367
Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success
Lovering, F., Bikker, J., & Humblet, C. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901241e · Cited by 4,495
Applications of Palladium-Catalyzed C–N Cross-Coupling Reactions
Ruiz-Castillo, P., & Buchwald, S. L. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00512 · Cited by 2,936
Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele
Middleton, P. G., Mall, M. A., Dřevínek, P., Lands, L. C., McKone, E. F., Polineni, D., Ramsey, B. W., Taylor-Cousar, J. L., Tullis, E., Vermeulen, F., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908639 · Cited by 2,198
Brown, D. G., & Boström, J. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01409 · Cited by 1,964
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Roberts, A. W., Davids, M. S., Pagel, J. M., Kahl, B. S., Puvvada, S. D., Gerecitano, J. F., Kipps, T. J., Anderson, M. A., Brown, J. R., Gressick, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1513257 · Cited by 1,900
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
Wainwright, C. E., Elborn, J. S., Ramsey, B. W., Marigowda, G., Huang, X., Cipolli, M., Colombo, C., Davies, J. C., De Boeck, K., Flume, P. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1409547 · Cited by 1,622
Induced protein degradation: an emerging drug discovery paradigm
Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486
Organic synthesis provides opportunities to transform drug discovery
Blakemore, D. C., Castro, L., Churcher, I., Rees, D. C., Thomas, A. W., Wilson, D. M., & Wood, A. (2018) · Nature Chemistry · doi:10.1038/s41557-018-0021-z · Cited by 1,485
Pd Metal Catalysts for Cross-Couplings and Related Reactions in the 21st Century: A Critical Review
Biffis, A., Centomo, P., Del Zotto, A., & Zecca, M. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00443 · Cited by 1,355
Liu, C., Zhou, Q., Li, Y., Garner, L. V., Watkins, S. P., Carter, L. J., Smoot, J., Gregg, A. C., Daniels, A. D., Jervey, S., et al. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00272 · Cited by 1,297
The future of cystic fibrosis care: a global perspective
Bell, S. C., Mall, M. A., Gutierrez, H., Macek, M., Madge, S., Davies, J. C., Burgel, P.-R., Tullis, E., Castaños, C., Castellani, C., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30337-6 · Cited by 974
Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del
Taylor-Cousar, J. L., Munck, A., McKone, E. F., van der Ent, C. K., Moeller, A., Simard, C., Wang, L. T., Ingenito, E. P., McKee, C., Lu, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709846 · Cited by 794
DNA-encoded chemistry: enabling the deeper sampling of chemical space
Goodnow, R. A., Dumelin, C. E., & Keefe, A. D. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.213 · Cited by 621
Vinylation of Grignard reagents. Catalysis by iron
Tamura, M., & Kochi, J. K. (1971) · Journal of the American Chemical Society · doi:10.1021/ja00735a030 · Cited by 603
Popovici-Muller, J., Lemieux, R. M., Artin, E., Saunders, J. O., Salituro, F. G., Travins, J., Cianchetta, G., Cai, Z., Zhou, D., Cui, D., et al. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00421 · Cited by 442
Recent Developments in Negishi Cross-Coupling Reactions
Haas, D., Hammann, J. M., Greiner, R., & Knochel, P. (2016) · ACS Catalysis · doi:10.1021/acscatal.5b02718 · Cited by 412
The Necessary Nitrogen Atom: A Versatile High-Impact Design Element for Multiparameter Optimization
Pennington, L. D., & Moustakas, D. T. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01807 · Cited by 408
PROTAC Technology: Opportunities and Challenges
Gao, H., Sun, X., & Rao, Y. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00597 · Cited by 345
Chemical Space of DNA-Encoded Libraries: Miniperspective
Franzini, R. M., & Randolph, C. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01874 · Cited by 271
Naylor, M. R., Bockus, A. T., Blanco, M.-J., & Lokey, R. S. (2017) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2017.04.012 · Cited by 185
Self-citationAbemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2– advanced breast cancer
Corona, S. P., & Generali, D. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s137783 · Cited by 174
Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein
Wang, M., Lu, J., Wang, M., Yang, C.-Y., & Wang, S. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00471 · Cited by 172
Lee, K. L., Ambler, C. M., Anderson, D. R., Boscoe, B. P., Bree, A. G., Brodfuehrer, J., Chang, J. S., Choi, C., Chung, S., Curran, K. J., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00231 · Cited by 162
Pelz, N. F., Bian, Z., Zhao, B., Shaw, S., Tarr, J. C., Belmar, J., Gregg, C., Camper, D. V., Goodwin, C. M., Arnold, A. L., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01660 · Cited by 159
First targeted protein degrader hits the clinic
Mullard, A. (2019) · Nature Reviews Drug Discovery · doi:10.1038/d41573-019-00043-6 · Cited by 146 · cited 2×
“PROTACs have become a new chemical modality [51] with some companies like Arvinas being pioneers [69] and any other phar aceutical co panies focusing on this approach.”
BackgroundTargeting IRAK4 for Degradation with PROTACs
Nunes, J., McGonagle, G. A., Eden, J., Kiritharan, G., Touzet, M., Lewell, X., Emery, J., Eidam, H., Harling, J. D., & Anderson, N. A. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00219 · Cited by 134 · cited 2×
“S focused their attention on targeting Interleukin−1 receptor-associated kinase 4 (IR 4) degradation utilizing the s all olecule PR T approach [73].”
MethodZhang, H., Zhao, H., Xi, X.-X., Liu, Y., Xin, M., Mao, S., Zhang, J., Lu, A., & Zhang, S. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112061 · Cited by 133
Mignani, S. M., Rodrigues, J., Tomás, H., Jalal, R., Singh, P. P., Majoral, J., & Vishwakarma, R. A. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.01.010 · Cited by 120
Stille coupling via C–N bond cleavage
Wang, D., Kawahata, M., Yang, Z., Miyamoto, K., Komagawa, S., Yamaguchi, K., Wang, C., & Uchiyama, M. (2016) · Nature Communications · doi:10.1038/ncomms12937 · Cited by 107
Kenakin, T. (2017) · Molecular Pharmacology · doi:10.1124/mol.117.108787 · Cited by 102
Industrial research: Drug companies must adopt green chemistry
Tucker, J. L., & Faul, M. M. (2016) · Nature · doi:10.1038/534027a · Cited by 89
What Do You Get from DNA-Encoded Libraries?
Satz, A. L. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00128 · Cited by 80
Small molecule PROTACs: an emerging technology for targeted therapy in drug discovery
Pei, H., Peng, Y., Zhao, Q., & Chen, Y. (2019) · RSC Advances · doi:10.1039/c9ra03423d · Cited by 76
Impact of Allosteric Modulation in Drug Discovery: Innovation in Emerging Chemical Modalities
Han, B., Salituro, F. G., & Blanco, M.-J. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00655 · Cited by 75
Self-citationDesign and Synthesis of Biaryl DNA-Encoded Libraries
Ding, Y., Franklin, G. J., DeLorey, J. L., Centrella, P. A., Mataruse, S., Clark, M., Skinner, S. R., & Belyanskaya, S. L. (2016) · ACS Combinatorial Science · doi:10.1021/acscombsci.6b00078 · Cited by 62
Beato, E. D. P., Priego, J., Gironda-Martínez, A., González‐Pérez, F., Benavides, J., de Blas, J., Martín-Ortega, M. D., Toledo, M. Á., Ezquerra, J., & Torrado, A. (2019) · ACS Combinatorial Science · doi:10.1021/acscombsci.8b00142 · Cited by 58
Li, J., Albrecht, J. W., Borovika, A., & Eastgate, M. D. (2017) · ACS Sustainable Chemistry & Engineering · doi:10.1021/acssuschemeng.7b03407 · Cited by 51
Landis, M. S., Bhattachar, S., Yazdanian, M. A., & Morrison, J. (2017) · AAPS PharmSciTech · doi:10.1208/s12249-017-0849-3 · Cited by 47
Targeted protein degradation mechanisms
Zhang, Y., Loh, C., Chen, J., & Mainolfi, N. (2019) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2019.01.001 · Cited by 45
How the antihypertensive losartan was discovered
Bhardwaj, G. (2006) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.1.6.609 · Cited by 40
Lasmiditan for the treatment of migraine
Capi, M., de Andrés, F., Lionetto, L., Gentile, G., Cipolla, F., Negro, A., Borro, M., Martelletti, P., & Curto, M. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1280457 · Cited by 40
Cyclization of RGD Peptides by Suzuki–Miyaura Cross-Coupling
Kemker, I., Schnepel, C., Schröder, D. C., Marion, A., & Sewald, N. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00360 · Cited by 39
Almaliti, J., Al-Hamashi, A. A., Negmeldin, A. T., Hanigan, C. L., Perera, L., Pflum, M. K. H., Casero, R. A., & Tillekeratne, L. M. V. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01271 · Cited by 30
A Facile Synthesis of Ligands for the von Hippel–Lindau E3 Ligase
Gütschow, M., Steinebach, C., Voell, S. A., Vu, L. P., Bricelj, A., Sosič, I., & Schnakenburg, G. (2020) · Synthesis · doi:10.1055/s-0040-1707400 · Cited by 26
Allosteric Modalities for Membrane-Bound Receptors: Insights from Drug Hunting for Brain Diseases
Coughlin, Q., Hopper, A. T., Blanco, M.-J., Tirunagaru, V. G., Robichaud, A. J., & Doller, D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01651 · Cited by 23
Self-citationPithani, S., Malmgren, M., Aurell, C., Nikitidis, G., & Friis, S. D. (2019) · Organic Process Research & Development · doi:10.1021/acs.oprd.9b00237 · Cited by 22
Hardouin, C., Baillard, S., Barière, F., Copin, C., Craquelin, A., Janvier, S., Lemaitre, S., Roux, S. L., Russo, O., & Samson, S. (2019) · Organic Process Research & Development · doi:10.1021/acs.oprd.9b00364 · Cited by 17
Blanco, M.-J. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9504-2_10 · Cited by 14
Self-citationDevelopability Assessment of Clinical Candidates
Bhattachar, S., Tan, J. S., & Bender, D. M. (2017) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-319-50042-3_7 · Cited by 7
Cited by
Bioisosteres of the Phenyl Ring: Recent Strategic Applications in Lead Optimization and Drug Design
Subbaiah, M. A. M., & Meanwell, N. A. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01215 · Cited by 710
Three-dimensional saturated C(sp3)-rich bioisosteres for benzene
Tsien, J., Hu, C., Merchant, R. R., & Qin, T. (2024) · Nature Reviews Chemistry · doi:10.1038/s41570-024-00623-0 · Cited by 263
Metadata
- Authors
- Buskes, M. J., & Blanco, M.-J.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2020-07-31
- Volume
- 25
- Issue
- 15
- Pages
- 3493
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W3046364841
- Cited by
- 296
- References
- 50
- FWCI
- 10.88
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.